moxetumomab pasudotox Report issue

Biologics mAb ADC Orphan Drug FDA Approved FDA Fast Track FDA Priority Review FDA

Active Ingredient History

  • Now
Moxetumomab pasudotox, sold under the brand name Lumoxiti, is an anti-CD22 immunotoxin medication for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Moxetumomab pasudotox is a CD22-directed cytotoxin and is the first of this type of treatment for adults with HCL. The drug consists of the binding fragment (Fv) of an anti-CD22 antibody fused to a toxin called PE38. This toxin is a 38 kDa fragment of Pseudomonas exotoxin A.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Payload: Pseudomonas exotoxin A
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

United States

$1598.1400 - $2080.0300
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

cat-8015 | ha22 | immunotoxin ha22 | moxetumomab pasudotox | moxetumomab pasudotox-tdfk


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue